TrialReader


Silver Doped Ceramic Coated Orthopedic Implants

NCT03343288 — Not applicable, Completed, 30 participants, Eskisehir Osmangazi University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

The Use of Silver Doped Calcium Phosphate Based Ceramic Coated Orthopedic Implants for Preventing Implant Related Infection

RegistryNCT03343288
StatusCompleted
PhaseNot applicable
Study typeInterventional; na, single group, masking: none, prevention
Enrollment30 (Actual)
SponsorEskisehir Osmangazi University (Other)
ConditionsImplant Site Infection, Implant Infection
InterventionsSilver doped hydroxyapatite coated implants (Device)
Datesstart 2017-03-15, primary completion 2020-03-15, completion 2020-03-15, first posted 2017-11-17, last updated 2020-07-22
Locations1 site in Turkey (Türkiye)

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Implant Site Infection All trials for Implant Infection All trials of Silver doped hydroxyapatite coated implants

-Summary

In this study, CE (European Conformity) marked, domestic manufactured standard orthopedic implants will be used after silver HA coating with electrospray method in 30 patients requiring hip joint prostheses, intramedullary nails or external fixator in 30 patients to antimicrobial effectiveness. These patients will be tasted for liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes,

Expand all sections  ·  Collapse all

+Detailed description

In this study, considering the differences in bone contact surface area and interactions; hip joint prostheses, intramedullary nails and external fixator implants to be used in 30 patients . CE (European Conformity) marked, domestic manufactured standard orthopedic implants will be used in patients after silver HA coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months. The performance of coating to be applied and any unwanted side effects in normal conditions of use will be evaluated..

+Arms and interventions

ArmTypeInterventionsDescription
Silver HA coated implantsExperimentalDevice: Silver doped hydroxyapatite coated implantsSilver doped hydroxyapatite coated implants
  • Silver doped hydroxyapatite coated implants (Device): In this study, CE marked, domestic manufactured standard orthopedic implants will be used in 30 patients after silver ceramic coating with electrospray method. These patients will be tasted for the evaluation of liver and kidney functions and blood and urine silver levels in addition to routine tests such as full blood, complete biochemistry, C-reactive protein, erythrocyte sedimentation rate required in the normal diagnosis and treatment processes, and will be monitored for at least 12 months.

+Outcome measures

Primary outcomes

  • Number of pin site with positive culture resuls [12 months]: incidence of pin tract infection

Secondary outcomes

  • Number of patient with elevated level of serum ALT levels [12 months]: liver dysfunction
  • Number of patient with elevated BUN levels [12 months]: Kidney dysfunction
  • Number of patient with elevated blood silver [12 months]: Silver exposure

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

1. Men and women between the ages of 18-65
2. Patients without heart, lung, renal or hepatic insufficiency
3. Patients without epilepsy, cerebrovascular attack or ischaemia
4. Patients without antibiotic allergy
5. Patients who have low immune defense mechanisms such as malignancy, diabetes mellitus, polytrauma, and open fracture
6. Patients using oral or parenteral corticosteroids, methotrexate, cyclosporine or other immunosuppressive drugs - -

Exclusion Criteria:

1. Pregnant women
2. Patients with another silver implant in their body, such as a silver-coated stent
3. Patients with known allergy or hypersensitivity to silver
4. Patients with too many antibiotics due to recurrent infections

+Locations (1)

FacilityCityCountryStatus
Eskisehir Osmangazi University HospitalEskişehirTurkey (Türkiye)

+Investigators

  • Nusret kose, MD, Principal investigator, Eskisehir Osmangazi University

My Notes